Navigation Links
UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation
Date:6/18/2013

University Hospitals Case Medical Center clinical researchers have launched an innovative clinical trial, unique in its design, which will evaluate the ability of a patient's own stem cells to prevent leg amputations in end stage peripheral arterial disease (PAD).

Led by Vik Kashyap, MD, Division Chief, Vascular Surgery at University Hospitals Case Medical Center's Harrington Heart & Vascular Institute and Professor of Surgery at Case Western Reserve University School of Medicine, the clinical trial is designed to improve blood flow in legs with blocked arteries by attempting to treat diseased blood vessels. Peripheral arterial disease (PAD) is a common yet serious disease that occurs when extra cholesterol and fat circulating in the blood collects on the walls of the arteries that supply blood to the limbs.

Due to the location and extent of the blockages in certain individuals, standard treatments such as surgical bypass (insertion of a vein or synthetic graft to redirect blood flow around the blockage) and angioplasty (insertion of a balloon through the artery to open the blockage) will not improve blood flow to the leg, and amputation is the only alternative.

For patients with critical limb ischemia (CLI) revascularization procedures such as surgical bypass or percutaneous angioplasty/stenting are currently the only option to restore perfusion and maintain limb viability.

For CLI patients who are non-candidates for revascularization, amputation is often needed. It is estimated that over 160,000 amputations are performed in the United States each year.

The number of CLI patients who will not be candidates for revascularization continues to rise as the population ages and the incidence of diabetes and other vascular risk factors increase. For CLI patients who are considered unreconstructable, the amputation and mortality rates at six months approach 40% and 20%, respectively. Furthermore, nearly 30% of patients who undergo below-knee amputation will fail rehabilitation and require chronic institutional care or professional assistance at home.

The trial sponsor, Biomet Biologics (Warsaw, IN), recently completed a Phase I study of 30 subjects to evaluate the safety of autologous concentrated bone marrow aspirate for critical limb ischemia. The results of this study were used to advance the company's MarrowStim concentration technology into the FDA-approved, pivotal IDE trial described here. Overall, the trial will enroll 152 subjects at up to 20 investigational sites.

"This trial offers an opportunity to save a patient's leg when there are no remaining options to improve blood supply," said Dr. Kashyap. "We are pleased to add this capability at UH and provide hope for patients facing the risk of limb loss."

Subjects will be randomized to receive either the investigational treatment involving the MarrowStim P.A.D. Kit (75% chance), or a placebo control involving a sham procedure (25% chance). The trial's primary end point of time to treatment failure, defined as major amputation or death, will be evaluated over a one‐year follow‐up period. Secondary end points, including rest pain, perfusion measurements, quality of life, and safety, will also be evaluated for one year.


'/>"/>

Contact: Mike Ferrari
mike.ferrari@uhhospitals.org
216-844-7239
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Physician Groups Call for Fewer Medical Tests
2. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
3. CAM therapy combined with conventional medical care may improve treatment of lower back pain
4. Image share project gives patients and physicians anytime, anywhere access to medical images
5. Researchers determine vitamin D blood level for reducing major medical risks in older adults
6. Biomedical researchers receive Hartwell Foundation awards
7. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
8. Fitness in Middle Age Lowers Medical Costs Later: Study
9. Ben-Gurion U. and Cincinnati Childrens Hospital to develop pediatric-specific medical technologies
10. Gene Tests May Not Drive Patients to More Medical Care
11. University studies and career expectations of medical students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s CEO ... Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about the lifestyle ... Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women access to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... and conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, ... packaged with the April edition of American Veterinarian™. , “We look ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... Angeles, CA (PRWEB) , ... March 27, 2017 , ... ... men with prostate cancer, including all stages, is more than 95%. Once the cancer ... drastically to less than 30%. To find out how to avoid this latter group, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... across multiple therapeutic areas, today announced that Amit Munshi , ... corporate update at the 16th Annual Needham Healthcare Conference on ... place April 4-5, 2017 at the Westin New York Grand ... A live audio webcast of the presentation will ...
(Date:3/24/2017)... Research and Markets has announced the ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report ... cell therapy manufacturing and focuses both on contract manufacturers and ... anticipated to emerge as viable alternatives to conventional treatment options. ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 According to ... Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators market was ... by 2022, growing at a CAGR of 3.6% during the forecast period. ... ... Allied Market Research Logo ...
Breaking Medicine Technology: